High PD-L1 expression was significantly associated with EGFR co-mutation with tumor suppressor genes such as TP53, while EGFR mutation alone was not associated with high PD-L1 expression, and these results might explain why advanced NSCLC patients with EGFR mutation alone showed poor response to immunotherapy and patients with EGFR/TP53 co-mutation were likely to benefit from anti-PD-1/PD-L1 treatment (97). The gene discussed is TP53; the disease is non-small cell lung carcinoma.